← SynDRA
EVOBRUTINIB
SynDRA canonical compound SYN0039249 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | BTK |
|---|
| Mechanism of action | Bruton's tyrosine kinase (BTK) inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BTK INHIBITOR
- Tyrosine-protein kinase BTK inhibitor
- Bruton's tyrosine kinase (BTK) inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- BMX
- CD69
- EGFR
- ERBB4
- GP6
- ITK
- KCNH2
- TEC
- BLK
- ERBB2
- JAK3
- LTK
- NUDT5
- TXK
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Msc-2364447c
- Msc2364447c
- M-2951
- M2951
- UNII-ZA45457L1K
- ZA45457L1K
- 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one
- 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
- Evobrutinib [INN]
- GTPL9752
- SCHEMBL14165673
- QUIWHXQETADMGN-UHFFFAOYSA-N
- MSC2364447C
- MSC-2364447C
- ZINC205623965
- AKOS032954004
- CS-6303
- MSC 2364447
- HY-101215
- A250 [WO2012170976]
- N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine
- 1-(4-((6-Amin
- evobrutinibum
- RefChem:139675
- US9580449, Example A39
- Evobrutinib?
- M-2951; Evobrutinib
- Evobrutinib (USAN/INN)
- EVOBRUTINIB [USAN]
- Evobrutinib (M-2951)
- EVOBRUTINIB [WHO-DD]
- BDBM291522
- BDBM291627
- EX-A2691
- US9580449, Example A250
- NSC800892
- s8777
- AB90800
Look up EVOBRUTINIB in the interactive SynDRA portal →